Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Tibolone Versus Transdermal E2/NETA on Sexual Function in Naturally Postmenopausal Women (P06089)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Physically and mentally healthy postmenopausal women, \>=48 and \<=68 years of age, with an intact uterus.~* Women were to suffer from decreased satisfactory sexual activity compared to younger age and sexual problems were not to be considered caused by relationship/partner problems. The decreased sexual functioning was to result in sexually related personal distress as confirmed by the FSDS (score =15).~* An affirmative answer was to be given to the following questions: (a) In previous years did you find sexual activity satisfying? (b) Has there been a decline in your satisfaction with sexual activity? (c) Are you satisfied with your partner as a friend?~* All subjects were to have an established sexual relationship of at least 6 months duration prior to screening.~* Women were to be sexually active.~* Normal mammography within 6 months prior to randomization.~* Body mass index \>18 and \<=32 kg/m2.~* Voluntary written informed consent~Exclusion Criteria:~* Any unexplained abnormal uterine bleeding~* Double layer endometrial thickness \>4 mm~* Tibolone or transdermal E2/NETA use within 3 months prior to screening~* Progestogen implants or injections and estrogen/progestogen injectable therapy within 6 months prior to screening~* Use of intra-uterine progestogen~* Unsuccessful previous treatment with androgens or compounds known to enhance androgenic activity~* Current successful treatment with androgens, without applying the applicable washout period of 3 months prior to screening~* Any previous or current unopposed estrogen administration, prior use of estrogen pellets or tamoxifen citrate (previous low dose vaginal estrogen-only applications are allowed)~* Use of anti -androgens within the preceding 5 years prior to screening.~* Women with significant organic disorder of sexual dysfunction or a partner with sexual dysfunction~* Women who had early onset sexual dysfunction (\>15 years prior to menopause)~* Women suffering from androgenic alopecia, acne or hirsutism~* Women suffering from illnesses influencing sexuality~* Women using medication influencing sexuality~* Moderate to severe depression~* Current or prior use of antidepressant within 8 weeks prior to screening~* Major gynecological surgery in the preceding 3 months~* Any serious disease or disorder; or any endocrine disorder with systemic disease which would have impaired overall health and well being (controlled hypo/hyperthyroidism and diabetes mellitus Type II was allowed)~* History or presence of severe psychiatric illness and/or any addictions to drugs, medication or alcohol in the past 3 years~* Diseases for which exogenous hormonal steroids were contraindicated.~* History or presence of any malignancy, except successfully treated non-melanoma skin cancers~* History or presence of cardiovascular or cerebrovascular conditions, thrombosis or thromboembolic disorders~* History or presence of liver, gallbladder or renal disease, epilepsy or classical migraine headaches~* Uncontrolled hypertension~* Women with abnormal cervical smear results~* History or presence of breast cancer, suspicious breast lump or mammographic abnormality~* Known hypersensitivity to any of the ingredients of the trial medication.~* Non-compliance with the screening diary~* Current use of raloxifene, clonidine, veralipride, phytoestrogen extracts~* Drugs known to interfere with the pharmacokinetics of the steroids~* Use of investigational drugs within the past 60 days~* Any disease or condition that was clinically relevant and which, in the opinion of the investigator, would have jeopardized the subject's well being during the course of the trial

- Gender: FEMALE
- Minimum Age: 48 Years
- Maximum Age: 68 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): tibolone
- 2 (Type: ACTIVE_COMPARATOR): transdermal continuous combined E2-NETA (estradiol-norethisterone)

Based on this trial design, predict the completion outcome and termination type (if applicable).